



PATENT
Docket No. 290.0010 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Michael S. Kinch et al.) Group Art Unit: 3254
)
Serial No.: 09/640,935) Examiner: Misook Yu
Confirmation No.: 3254)
)
Filed: 17 August 2000)
)
For: EPHA2 AS A THERAPEUTIC TARGET FOR METASTATIC
CANCER (As Amended)

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents
Washington D.C. 20231

Dear Sir:

The Office Action mailed August 14, 2002, has been received and carefully reviewed.
Please amend the above-identified application as follows:

In the Specification

Please replace the paragraph beginning at page 5, line 6, with the following rewritten paragraph. Pursuant to 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

EphA2 is expressed differently in normal and metastatic cells. In normal breast and prostate epithelial cells, EphA2 is enriched in within cites of cell adhesion. Conversely, in metastatic prostate cells EphA2 is diffusely distributed, and in metastatic breast cancer cells EphA2 is redistributed into the membrane ruffles. EphA2 expression is also known to be altered in lung and colon malignancies, and it is believed that EphA2 altered expression occurs in other